Live cell imaging is revolutionizing drug discovery by enhancing translational predictability and streamlining lead optimization processes. This innovative technology provides real-time, dynamic insights into cellular mechanisms, allowing researchers to examine drug effects across various cellular models with greater accuracy. By integrating fluorescence reporters, label-free techniques, and advanced artificial intelligence (AI) and machine learning (ML) methodologies, high-content imaging facilitates detailed phenotypic screening and compound profiling.
European Leaders in Live Cell Imaging
Several leading European biotech companies are pioneering live cell imaging technologies, significantly contributing to the advancement of drug discovery. Notable players include Cellbox Labs, Evotec SE, Nanolive SA, and Salipro Biotech AB, each developing unique methodologies to improve in vitro–in vivo translation and accelerate the identification of new chemical entities (NCEs).
Innovative Approaches by Cellbox Labs
Founded in 2020 in Latvia, Cellbox Labs specializes in modular “organ-on-chip” (OOC) systems designed to enhance drug discovery. These systems mimic various organs, including the blood-brain barrier, kidney, gut, lung, and pancreas, by layering endothelial and epithelial cells in controlled environments. Such OOCs facilitate accurate predictions of individual responses to drugs, food, and probiotics.
In recent funding rounds, Cellbox Labs successfully raised nearly €4.3 million to expand its OOC high-throughput technology and integrate biological sensors, thereby improving in vitro–in vivo extrapolation (IVIVE). Collaborations with esteemed institutions aim to develop a vascularized Gut-Brain-Axis platform, potentially transforming real-world drug evaluation.
Evotec SE’s Patient-Centric Models
Germany’s Evotec SE utilizes induced pluripotent stem cell (iPSC) technology to model human diseases and enable patient-specific drug testing. The company has transitioned from traditional 2D cultures to more physiologically relevant models such as organoids and co-cultures. By integrating live-cell imaging with iPSC-derived cell types, Evotec focuses on conditions like neurodegenerative and metabolic diseases.
Strategic collaborations with major biopharma companies, including Boehringer Ingelheim and Bristol Myers Squibb, have yielded significant advancements. Evotec’s innovative approaches have led to successful Phase II clinical trials and the establishment of a robust pipeline for future drug candidates.
Nanolive SA’s Label-Free Imaging
Headquartered in Switzerland, Nanolive SA offers label-free holotomographic imaging platforms that enable continuous live-cell observation without fluorescent markers. This technology allows researchers to assess cellular dynamics and viability in real time, making it an asset in the development of immunotherapies such as CAR-T and TCR-T cells.
Nanolive’s recent innovations include the Smart Mitochondrial AssayLIVE, which provides insights into metabolic function and drug-induced toxicity. This capability is crucial for researchers targeting NCEs in oncology and mitochondrial diseases, further enhancing the drug discovery landscape.
Salipro Biotech AB’s Membrane Protein Focus
Sweden’s Salipro Biotech AB specializes in stabilizing membrane proteins using its proprietary Salipro DirectMX technology. This platform aids in the development of therapeutic antibodies and small molecules that target challenging proteins, including G-protein-coupled receptors and ion channels.
Recent collaborations with industry giants have demonstrated Salipro’s capability to identify small-molecule binders against difficult membrane protein targets. By combining its technology with other platforms, Salipro is unlocking new drug targets and enhancing the overall drug discovery process.
Future Potential of Live Cell Imaging
The global live cell imaging market is projected to experience substantial growth, with estimates indicating it could reach approximately $6.73 billion by 2034. This growth reflects the increasing demand for phenotypically and mechanistically informed screening methodologies that facilitate drug discovery and personalized medicine.
Regulatory bodies are also moving towards phasing out animal testing, promoting the adoption of innovative methodologies such as OOCs and live-cell imaging. As advanced cell models and AI/ML analytics converge, a new generation of discovery platforms is emerging, enabling quicker identification and validation of NCEs for clinical trials.
Key Takeaways
- Live cell imaging enhances drug discovery by providing dynamic insights into cellular processes.
- European biotechs like Cellbox Labs and Evotec are at the forefront of innovative drug discovery methodologies.
- Collaborations among industry leaders are accelerating the development of patient-centric models and novel therapies.
- The market for live cell imaging is poised for significant growth, driven by regulatory shifts and technological advancements.
- OOCs and AI integration are transforming the landscape, potentially reducing drug attrition rates and improving clinical trial outcomes.
In conclusion, the advancements in live cell imaging represent a paradigm shift in drug discovery, fostering more accurate predictions and faster development timelines. As the industry embraces these innovations, the potential for improved patient outcomes and groundbreaking therapies becomes increasingly attainable. The future of drug discovery is undoubtedly bright, driven by the collaborative efforts and pioneering technologies of these leading biotech firms.
Read more → www.pharmtech.com